Breast Cancer

Latest News

USPSTF Recommends Women Begin Undergoing Mammograms at 40 Years Old
USPSTF Recommends Women Begin Undergoing Mammograms at 40 Years Old

May 3rd 2024

The final breast cancer screening recommendation from the United States Preventive Services Task Force advises that women aged 40 should begin biennial screening.

Trastuzumab Deruxtecan Enhances PFS in Metastatic HR+/HER2-Low Breast Cancer
Trastuzumab Deruxtecan Enhances PFS in Metastatic HR+/HER2-Low Breast Cancer

April 30th 2024

ADCs Associated With Fatigue Among Patients With Breast Cancer
ADCs Associated With Fatigue Among Patients With Breast Cancer

April 29th 2024

Trastuzumab Biosimilar Receives FDA Approval for HER2-Overexpressing Breast and Gastric/GEJ Cancers
Trastuzumab Biosimilar Receives FDA Approval for HER2-Overexpressing Breast and Gastric/GEJ Cancers

April 29th 2024

Nurse Intervention Approach Feasible in Addressing Cancer Symptom Clusters
Nurse Intervention Approach Feasible in Addressing Cancer Symptom Clusters

April 28th 2024

Latest CME Events & Activities

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

Register Now!

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

© 2024 MJH Life Sciences

All rights reserved.